CN103387568A - Compounds, preparation method thereof and applications thereof - Google Patents
Compounds, preparation method thereof and applications thereof Download PDFInfo
- Publication number
- CN103387568A CN103387568A CN2013103080978A CN201310308097A CN103387568A CN 103387568 A CN103387568 A CN 103387568A CN 2013103080978 A CN2013103080978 A CN 2013103080978A CN 201310308097 A CN201310308097 A CN 201310308097A CN 103387568 A CN103387568 A CN 103387568A
- Authority
- CN
- China
- Prior art keywords
- present
- cell
- compound
- formula
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(N(*)[C@@](CCC1)CN1C(c1ccc(*)cc1)=O)=O Chemical compound *C(N(*)[C@@](CCC1)CN1C(c1ccc(*)cc1)=O)=O 0.000 description 2
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of anticancer medicines, and particularly relates to compounds having antineoplastic activity and having a general formula I, a preparation method thereof, pharmaceutical compositions thereof and applications thereof, wherein definition of each group is described in the specification.
Description
Technical field
The present invention relates to antitumor relevant pharmaceutical field.Particularly, the present invention relates to pyrazole amide analog derivative that has antitumor action and preparation method thereof, and the pharmaceutical composition that contains them.
Background technology
Cancer is the primary disease that threatens the human life, and according to statistics, annual global cancer mortality sum reaches 7,000,000 people, and China dies from patient more than 100 ten thousand people of tumour every year, and increases gradually, has become first cause of the death of urban population.At present China clinically the medicine of traditional treatment Cancerous disease have a lot, result for the treatment of is also more obvious clinically for they, but shortcoming is: specificity is low, and poor selectivity causes obvious toxic side effect, easily produces serious cancer multidrug resistance phenomenon.
Along with molecular biological development, current anticancer medicine is just from traditional cytotoxic drug, new type anticancer disease drug development to the too many levels effect for mechanism, in the novel targets of the antitumous effect of paying close attention at present both at home and abroad one of important be exactly protein tyrosine kinase (Huang Min, fourth is strong, the antitumor drug novel targets, " Chinese prescription drugs ", 2006,12 (57), 10-15).Protein tyrosine kinase has at present and surpasses 20 acceptors that adhere to different families separately and nonreceptor tyrosine kinase and be used as target and carry out screening anticancer medicine, its inhibitor has had several listings, in order to find active better medicine, molecular targeted anti-tumor agents treatment in recent years proposes again another challenge concept: many targets Tyrosylprotein kinase suppresses the strategy of (multiple targeted tyrosine kinase inhibition), is antineoplastic important direction.
The invention discloses the protein tyrosine kinase inhibitor that a class contains the pyrazole amide structure, can be for the preparation of antitumor drug.
Summary of the invention
An object of the present invention is to provide a kind of protein tyrosine kinase inhibitor that contains the pyrazole amide structure with general formula I.
Another object of the present invention is to provide preparation and has the compound of general formula I.
A further object of the present invention is to provide and contains the purposes of compound of Formula I at anti-tumor aspect.
Now in conjunction with purpose of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula I has following structural formula:
Wherein,
R
1Be selected from F, Cl, Br, I;
R
2Be selected from the alkyl of H, C1-C3;
m=1-3。
It is as follows that preferred the present invention has the compound of general formula I:
Compound of Formula I of the present invention is synthesized by following steps:
Compd A and compd B react in suitable solvent under alkali exists, can obtain Compound I.Wherein said alkali is selected from triethylamine, diisopropyl ethyl amine, KOH, NaOH, salt of wormwood, sodium carbonate, sodium ethylate, sodium hydride, and solvent is selected from trichloromethane, methylene dichloride, acetonitrile, DMF etc.This reaction can use salt compounded of iodine as catalyzer, as KI and NaI etc.
Compound of Formula I of the present invention has the restraining effect for cancer, can be used as the medicine of effective constituent for the preparation of the cancer aspect.The activity of compound of Formula I of the present invention is by the extracorporeal anti-tumor modelling verification.
Compound of Formula I of the present invention is effective in quite wide dosage range.The actual dosage of taking compound of Formula I of the present invention can be decided according to relevant situation by the doctor.These situations comprise: the person's of being treated physical state, route of administration, age, body weight, to the individual reaction of medicine, the severity of symptom etc.
Embodiment
The present invention is further illustrated below in conjunction with embodiment.Need to prove, following embodiment is only for explanation, and not is used for restriction the present invention.The various variations that those skilled in the art's training centre according to the present invention is made all should be within the desired protection domain of the application's claim.
Embodiment 1
Reaction raw materials: self-control, ordinary method.
3.43g (10mmol) compd A-1 and 2.16g (10mmol) compd B-1 is dissolved in the MeCN of 20mL drying, then adds 4.15g (30mmol) salt of wormwood, then reflux is spent the night in nitrogen atmosphere.Reaction mixture is poured in frozen water,, with the dichloromethane extraction of 50mL * 3, merge organic phase and wash with salt solution, anhydrous sodium sulfate drying, boil off solvent revolving to steam on instrument, obtain the crude product of I-1, column chromatography purification, obtain the sterling of I-1, white solid, mp204-207 ℃, MS, m/z=496 ([M+NH
4]
+).
Embodiment 2
3.43g (10mmol) compd A-1 and 2.16g (10mmol) compd B-1 is dissolved in the DMF of 20mL drying, then adds 4.15g (30mmol) salt of wormwood and 0.50g potassiumiodide, then reflux is spent the night in nitrogen atmosphere.Reaction mixture is poured in frozen water,, with the dichloromethane extraction of 50mL * 3, merge organic phase and wash with salt solution, anhydrous sodium sulfate drying, boil off solvent revolving to steam on instrument, obtain the crude product of I-1, column chromatography purification, obtain the sterling of I-1, white solid, mp204-207 ℃, MS, m/z=496 ([M+NH
4]
+).
Embodiment 3-8
, with reference to the operation of embodiment 1 and 2, has the compound of formula I in synthetic following table.
Embodiment 9
(1) material
Cell strain: leukemia HL-60 cell, gastric cancer SGC-7901 cell line, MCF-7 Breast Cancer Cell, lung cancer cell A-549, all available from Shanghai cell research institute of the Chinese Academy of Sciences.
Reagent: MTT, the Amresco packing; The DMEM substratum, Gibco; Calf serum, Lanzhou people's marine life; Trypsinase, the Amresco packing; Fluorouracil Injection, 0.25g/10ml (propping up), Tianjin gold credit amino acid company limited.
Instrument: Bechtop, Suzhou Decontamination Equipment Plant; CO
2Incubator, Thermo company, model: HERA Cel1150; Inverted microscope, Carl Zeiss company, model: Axiovert200; Enzyme-linked immunosorbent assay instrument, TECAN company, model: Sunrise; Whizzer, Kerdro company, model: Heraeus.
(2) method
Cell cultures: tumor cell inoculation is containing 10% calf serum, in the DMEM nutrient solution of 100IU/ml penicillin G sodium salt and 100ug/ml Vetstrep, puts 37 ℃, 100% relative humidity, contains 5%CO
2Incubator in, go down to posterity standby after 3 times.
Mtt assay is measured: the cell in the vegetative period of taking the logarithm, after 0.25% tryptic digestion (suspension cell need not digest), be suspended in the DMEM nutrient solution that contains 10% calf serum, with the glass dropper, blow and beat into gently single cell suspension, microscopically blood cell counts plate numeration viable cell.(cell concn is adjusted into 6～8 * 10 to the 96 every hole of well culture plate inoculating cell suspension 90 μ l
4Individual/ml), at 37 ℃, 100% relative humidity, contain 5%CO
2, 95% air incubator cultivate 24h after, every hole adds 5 μ l liquids (final concentration is 10 μ g/ml).In addition, each concentration is established negative control (isoconcentration DMSO) and blank background (not adding cell), and each group is all established 6 multiple holes.Cultured continuously 48h again, then every hole adds the MTT solution of 10 μ l5mg/ml, after continuing to cultivate 4h, carefully suck supernatant liquor (suspension cell, need first centrifugal, then suck supernatant).Every hole adds 100 μ l DMSO, puts the micro oscillator concussion so that crystallization is dissolved fully, and the single wavelength colorimetric of microplate reader 492nm, measure the OD value.The following method of using is calculated inhibitory rate of cell growth as evaluation index.
Inhibiting rate (%)=[1-(experimental group OD average-blank group OD average)/(control group OD average-blank group OD average)] * 100%.
(3) result
The inhibiting rate (%) of table 1. sample to cultured tumor cells in vitro
(4) conclusion
Can find out from above-mentioned in vitro tests result, compound of Formula I of the present invention all has stronger restraining effect to these 4 kinds of human cancer cells after interaction in vitro 48h when 10 μ g/ml concentration.
Claims (3)
1. the compound that has general formula I:
Wherein,
R
1Be selected from F, Cl, Br, I;
R
2Be selected from the alkyl of H, C1-C3;
m=1-3。
2. the defined compound of Formula I of claim 1 or its pharmacy acceptable salt are selected from:
3. the defined compound of Formula I of claim 1-3 is in the purposes for preparing aspect antitumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310308097.8A CN103387568B (en) | 2013-07-16 | 2013-07-16 | Compounds, preparation method thereof and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310308097.8A CN103387568B (en) | 2013-07-16 | 2013-07-16 | Compounds, preparation method thereof and applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103387568A true CN103387568A (en) | 2013-11-13 |
| CN103387568B CN103387568B (en) | 2014-11-05 |
Family
ID=49532000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310308097.8A Expired - Fee Related CN103387568B (en) | 2013-07-16 | 2013-07-16 | Compounds, preparation method thereof and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103387568B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998042342A1 (en) * | 1997-03-24 | 1998-10-01 | Merck & Co., Inc. | Thrombin inhibitors |
| CN102757422A (en) * | 2011-04-29 | 2012-10-31 | 赛诺菲 | Derivatives of N-[(1H-pyrazol-1-yl)aryl]-1H-indole or 1H- indazole-3-carboxamide and their therapeutic uses as p2y12 antagonists |
| CN102811619A (en) * | 2009-11-13 | 2012-12-05 | 金纳斯克公司 | Kinase inhibitors |
| CN102812022A (en) * | 2010-01-12 | 2012-12-05 | Ab科学有限公司 | Thiazole and oxazole kinase inhibitors |
-
2013
- 2013-07-16 CN CN201310308097.8A patent/CN103387568B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998042342A1 (en) * | 1997-03-24 | 1998-10-01 | Merck & Co., Inc. | Thrombin inhibitors |
| CN102811619A (en) * | 2009-11-13 | 2012-12-05 | 金纳斯克公司 | Kinase inhibitors |
| CN102812022A (en) * | 2010-01-12 | 2012-12-05 | Ab科学有限公司 | Thiazole and oxazole kinase inhibitors |
| CN102757422A (en) * | 2011-04-29 | 2012-10-31 | 赛诺菲 | Derivatives of N-[(1H-pyrazol-1-yl)aryl]-1H-indole or 1H- indazole-3-carboxamide and their therapeutic uses as p2y12 antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103387568B (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3398598B1 (en) | Sulfonamide derivative and preparation method and use thereof | |
| CN103450176A (en) | Naphthalimide compound containing 2-(4-aminophenyl) benzothiazole and application thereof | |
| CN103396400B (en) | Pyrazole amide compounds, and preparation method and application thereof | |
| CN102250150B (en) | Organic hydridized tetra-core platinum complex and preparation method thereof as well as application in antitumor medicament preparation | |
| CN111808117A (en) | Artemisinin-anilinoquinazoline D-type derivative, and pharmaceutical composition and application thereof | |
| CN102911118B (en) | Benzo-azepine type derivative and preparation method and purpose thereof | |
| CN104230912A (en) | Quinoline derivative as well as preparation method and application thereof | |
| CN110028482B (en) | 4-position split melphalan nitrogen mustard derivative of brefeldin A and preparation method and application thereof | |
| CN103387568B (en) | Compounds, preparation method thereof and applications thereof | |
| CN103387569B (en) | Antineoplastic compounds, preparation method thereof and applications thereof | |
| CN103382198B (en) | Pyrazole amide compound, and preparation method thereof and application | |
| CN103382202B (en) | Compound containing furan substitute and preparation method and use thereof | |
| CN103420993B (en) | Thiophene substituent group-containing compound as well as preparation method and application thereof | |
| CN103408541B (en) | Indole-substituted thiazolo cyclohexane compound and antineoplastic applications thereof | |
| CN101974016A (en) | Amide compound and preparation method and applications thereof | |
| CN103396414B (en) | Imidazolyl-substituted thiazocyclohexane compounds and antitumor application thereof | |
| CN103435572B (en) | Thiazolocyclohexane compounds, and preparation methods and antitumor uses thereof | |
| CN103483414A (en) | 4-azasteroid purine nucleoside analog, and preparation and application thereof | |
| CN110028480B (en) | 4, 7-position split melphalan nitrogen mustard derivative of brefeldin A and preparation method and application thereof | |
| CN103435573B (en) | Benzyl-substituted thiazolocyclohexane compounds, and preparation methods and antitumor uses thereof | |
| CN103382190B (en) | Thiazole-cyclohexane compound of same category and preparation method and purpose thereof | |
| CN103467452B (en) | A kind of benzamide compound and application thereof | |
| CN103265537B (en) | Antitumor compounds, preparation method and application thereof | |
| CN103265535B (en) | Antitumor compounds, preparation method and application thereof | |
| CN110028481B (en) | Preparation method and application of 7-position split melphalan nitrogen mustard derivative of brefeldin A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141105 Termination date: 20170716 |